Bedaquiline: A Novel Addition to Anti-Tubercular Armamentarium
Year: 2013
Type: article
Abstract: In current scenario of rising trend of resistant tuberculosis (TB) and acquired immunodeficiency syndrome (AIDS) co infection with TB, a novel antitubercular drug is a prime need to effectively decrease the disease burden. In lieu of the fact that no new antitubercular drug has come up in last four decades, bedaquiline (TMC 207), an arylquinoline, seems an attractive option for TB patients because of its tendency to cause earlier and sustained antitubercular action, shorten treatment duration, less chances of resistance and better safety as compared to existing second line drugs. Bedaquiline has recently been approved by USFDA on 28th December, 2012 for treating multi drug resistant TB (MDR-TB) in adults ≥18 years. This review elucidates the available evidence on efficacy and safety of this drug after analyzing preclinical and clinical studies. Searches of pubmed, Cochrane database, Medscape, Google and clinicaltrial.org were made for terms like bedaquiline, TMC207 and MDR-TB. KEY WORDS: Bedaquiline, TMC207, pulmonary tuberculosis, MDR-TB
Author: Ruchika Nandha
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W2339242137